Dendreon Corp (DNDNQ) 0.0325 $DNDNQ
World Anti-Inflammatory Therapeutics Market Report - Analysis, Opportunities, Trends & Forecasts 2015-2020
M2 - Fri Dec 04, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5qc7p/world) has announced the addition of the "World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020" report to their offering. Benefits of this Report: - The report provides a quantitative analysis of the current market and estimations during 2014 - 2020 that assist in identifying the prevailing market opportunities to capitalize - Exhaustive analysis of the global anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics that are currently being used along with the categories that would gain prominence in the future - Competitive intelligence (of leading manufacturers and distributors of anti-inflammatory therapeutics) helps in understanding the competitive scenario across the geographies - Comprehensive analysis of factors that drive and restrict the growth of the global anti-inflammatory therapeutics market is provided - SWOT analysis enables to study the internal environment of the leading companies for strategy formulation - The Country level analysis of anti-inflammatory therapeutics market conditions has been provided in this report Key Findings: - North America CRPC market spearheads the regional CRPC markets and would continue to lead throughout the forecast period - Radiotherapy segment is projected to grow at a CAGR of 24.5% throughout the forecast period, fastest among all CRPC therapy segments - Immunotherapy segment is expected to grow more than threefold over the forecast period - European market is expected to expand more than two-fold as compared to North American market (within hormonal therapy segment) over the forecast period - Countries like India and China holds immense future market potential as there is a higher count of undiagnosed CRPC patients - The principal and key strategy adopted by the leading players in the market is product launch. In order to implement the strategy, acquisitions and partnerships/collaborations have been the key strategies adopted by the leading industry players. The key companies profiled in the report are Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others Companies Mentioned: - Abbvie - Amgen - AstraZeneca PLC - Eli Lily and Company - F. Hoffman - GlaxoSmithKline - Johnson & Johnson - La Roche AG - Merck & CO. - Novartis - Pfizer Report Structure: Chapter: 1 INTRODUCTION Chapter: 2 EXECUTIVE SUMMARY Chapter: 3 MARKET OVERVIEW Chapter: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION Chapter: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS Chapter: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY Chapter: 7 COMPANY PROFILES For more information visit http://www.researchandmarkets.com/research/l5qc7p/world
JNJ: 117.71 (+0.10), MRK: 61.48 (-0.33), AZN: 33.12 (+0.38), AMGN: 169.96 (+0.66), GSK: 43.10 (+0.59), NVS: 79.21 (+0.09)
Stoltmann Law Offices Investigates Marcus J. Debaise and Wells Fargo Advisors
GlobeNewswire - Mon Nov 09, 5:00PM CST
CHICAGO-- Stoltmann Law Offices announces it is investigating former Wells Fargo and Wachovia Securities financial adviser Marcus J. Debaise (CRD# 2404266) of Glastonbury, Connecticut. Debaise may have over-concentrated and failed to diversify the portfolio of retirees in a variety of equity investments. These investments include, but are not limited to, MFC Corp., KHD Wedag International, Compton Petroleum Corp., Niko Resources, Ltd., Presstek Inc., Essex Rental Corp., Fusion-IO Inc., GMX Resources, Inc., Amarin Corporation PCL, Bankers Petroleum, Xtreme Drilling & Coil, Myriad PhArmaceuticals, FAB Universal Corp, Dendreon Corp., Galleon Energy, Inc., ATP Oil & Gas, China Mediaexpress Holdings, Aviat Networks, Inc., Dryships, Inc., Turnkey E&P Inc., TESCO, Walter Energy, National Oilwell, Varco, Inc., Carrington Labs, Inc., Regis Corp Minn, Talisman Energy, Inc., Mosaic Company, Carrizo Oil & Gas, Petrohawk Energy Corp., United Therepeutics Corp., Black Diamond, Inc., Orient Express Hotels Ltd - A, Bioenvision Inc., Liveperson, Inc., DVI, Inc., Harris Stratex Networks, ICJ Medical, Inc., CV Therapeutics, and Middleby Corporation. Marcus Debaise is now subject to 17 customer disputes since 2011, many of which relate to the over-concentration of investor portfolios in equities.
HK: 9.00 (-0.31), TLM: 7.99 (unch), AMRN: 2.72 (-0.12), WFC: 47.12 (+0.16), MOS: 25.80 (-0.69), CRZO: 33.74 (-1.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 1.40 (unch), BIIB: 300.71 (+3.30), NWBO: 0.51 (-0.06), MBVX: 5.46 (+0.11), CVM: 0.39 (+0.01), CLDX: 3.66 (+0.08), MACK: 4.67 (+0.05), INO: 9.36 (+0.14), NLNK: 10.49 (+0.24), JUNO: 28.28 (-0.14), GALE: 0.32 (-0.03), IMMU: 2.91 (+0.06), ADXS: 10.54 (+0.14), ADRO: 13.70 (+0.10), IMGN: 2.84 (+0.08), AMGN: 169.96 (+0.66), SPPI: 5.05 (-0.44), LLY: 78.24 (-0.24), BMY: 55.33 (-0.27), GSK: 43.10 (+0.59), SRNE: 6.83 (+0.04), ONTY: 1.21 (+0.02), IMUC: 0.12 (unch), PGNX: 6.12 (+0.05), ARGS: 4.92 (+0.06), BLCM: 19.08 (+0.81), SGEN: 53.78 (+2.08), KITE: 54.63 (-0.47), MRK: 61.48 (-0.33)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 9.36 (+0.14), NWBO: 0.51 (-0.06), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), GALE: 0.32 (-0.03), GSK: 43.10 (+0.59), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Dendritic Cell and CAR-T Therapies Market, 2014 - 2024
PR Newswire - Tue Aug 18, 11:57AM CDT
INTRODUCTIONCancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
Global Cancer Immunotherapy Market Outlook 2020
M2 - Fri Jun 12, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3t28xc/global_cancer) has announced the addition of the "Global Cancer Immunotherapy Market Outlook 2020" report to their offering. Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects. Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years. Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts. Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data. New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future. Cancer Immunotherapies Included in Report: Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines "Global Cancer Immunotherapy Market Outlook 2020" Report Highlight: - Introduction & Classification of Cancer Immunotherapy - Global Cancer Immunotherapy Pipeline by Company, Indication & Phase - Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication - Global Cancer Immunotherapy Pipeline: 1834 Drugs - Marketed Cancer Immunotherapies: 113 Drugs - Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb - Cancer Vaccines Pipeline: 312 Vaccines - Marketed Cancer mAb: 36 mAb - Marketed Cancer Vaccines: 12 Vaccines Key Topics Covered: 1. Introduction to Cancer Immunotherapy 2. Classification of Cancer Immunotherapy 3. Cancer Immunotherapy by Vaccines 4. Cancer Immunotherapy by Monoclonal Antibodies 5. Cancer Immunotherapy by Adoptive Cell Transfer 6. Cancer Immunotherapy by Immune Checkpoint Inhibitors 7. Cancer Immunotherapy by Immunomodulators 8. Cancer Immunotherapy by Cytokines 9. Cancer Immunotherapy by Interleukins 10. Cancer Immunotherapy by Interferon 11. Cancer Immunotherapy by GM-CSF 12. Cancer Immunotherapy Market Overview 13. Global Cancer Immunotherapy Market Dynamics 14. Global Cancer Immunotherapy Market Future Prospects 15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase 16. Marketed Cancer Cell Therapies Drugs Clinical Insight 17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase 18. Marketed Cancer Cytokines Drugs Clinical Insight 19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase 20. Marketed Cancer Immunomodulators Clinical Insight 21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase 22. Marketed Cancer Vaccines Clinical Insight 23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase 24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight 25. Competitive Landscape - Abbvie - Advaxis - Altor BioScience - Amgen - Biogen Idec - Biogenomics - Celldex Therapeutics - Dendreon Corporation - Eli Lilly - Expression Genetics - Galena Biopharma - Genmab - Gilead Sciences - GlaxoSmithKline - IRX Therapeutics - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Pfizer - Philogen - Regulon - Roche - Seattle Genetics - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/3t...bal_cancer
INO: 9.36 (+0.14), BIIB: 300.71 (+3.30), NWBO: 0.51 (-0.06), GILD: 77.76 (-0.30), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), AMGN: 169.96 (+0.66), GALE: 0.32 (-0.03), LLY: 78.24 (-0.24), GSK: 43.10 (+0.59), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 117.71 (+0.10), INO: 9.36 (+0.14), NWBO: 0.51 (-0.06), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), GALE: 0.32 (-0.03), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 33.96 (-0.08), AMRN: 2.72 (-0.12)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
BusinessWire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 27.46 (-0.07), VRX.TO: 36.21 (-0.08)
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
CNW Group - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE(®) (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon"
. In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014.
VRX: 27.46 (-0.07), VRX.TO: 36.21 (-0.08)
World Anti-Inflammatory Therapeutics Market Report - Analysis, Opportunities, Trends & Forecasts 2015-2020
M2 - Fri Dec 04, 3:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5qc7p/world) has announced the addition of the "World Anti-Inflammatory Therapeutics - Market Opportunities and Forecasts, 2014 - 2020" report to their offering. Benefits of this Report: - The report provides a quantitative analysis of the current market and estimations during 2014 - 2020 that assist in identifying the prevailing market opportunities to capitalize - Exhaustive analysis of the global anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics that are currently being used along with the categories that would gain prominence in the future - Competitive intelligence (of leading manufacturers and distributors of anti-inflammatory therapeutics) helps in understanding the competitive scenario across the geographies - Comprehensive analysis of factors that drive and restrict the growth of the global anti-inflammatory therapeutics market is provided - SWOT analysis enables to study the internal environment of the leading companies for strategy formulation - The Country level analysis of anti-inflammatory therapeutics market conditions has been provided in this report Key Findings: - North America CRPC market spearheads the regional CRPC markets and would continue to lead throughout the forecast period - Radiotherapy segment is projected to grow at a CAGR of 24.5% throughout the forecast period, fastest among all CRPC therapy segments - Immunotherapy segment is expected to grow more than threefold over the forecast period - European market is expected to expand more than two-fold as compared to North American market (within hormonal therapy segment) over the forecast period - Countries like India and China holds immense future market potential as there is a higher count of undiagnosed CRPC patients - The principal and key strategy adopted by the leading players in the market is product launch. In order to implement the strategy, acquisitions and partnerships/collaborations have been the key strategies adopted by the leading industry players. The key companies profiled in the report are Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others Companies Mentioned: - Abbvie - Amgen - AstraZeneca PLC - Eli Lily and Company - F. Hoffman - GlaxoSmithKline - Johnson & Johnson - La Roche AG - Merck & CO. - Novartis - Pfizer Report Structure: Chapter: 1 INTRODUCTION Chapter: 2 EXECUTIVE SUMMARY Chapter: 3 MARKET OVERVIEW Chapter: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION Chapter: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS Chapter: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY Chapter: 7 COMPANY PROFILES For more information visit http://www.researchandmarkets.com/research/l5qc7p/world
JNJ: 117.71 (+0.10), MRK: 61.48 (-0.33), AZN: 33.12 (+0.38), AMGN: 169.96 (+0.66), GSK: 43.10 (+0.59), NVS: 79.21 (+0.09)
Stoltmann Law Offices Investigates Marcus J. Debaise and Wells Fargo Advisors
GlobeNewswire - Mon Nov 09, 5:00PM CST
CHICAGO-- Stoltmann Law Offices announces it is investigating former Wells Fargo and Wachovia Securities financial adviser Marcus J. Debaise (CRD# 2404266) of Glastonbury, Connecticut. Debaise may have over-concentrated and failed to diversify the portfolio of retirees in a variety of equity investments. These investments include, but are not limited to, MFC Corp., KHD Wedag International, Compton Petroleum Corp., Niko Resources, Ltd., Presstek Inc., Essex Rental Corp., Fusion-IO Inc., GMX Resources, Inc., Amarin Corporation PCL, Bankers Petroleum, Xtreme Drilling & Coil, Myriad PhArmaceuticals, FAB Universal Corp, Dendreon Corp., Galleon Energy, Inc., ATP Oil & Gas, China Mediaexpress Holdings, Aviat Networks, Inc., Dryships, Inc., Turnkey E&P Inc., TESCO, Walter Energy, National Oilwell, Varco, Inc., Carrington Labs, Inc., Regis Corp Minn, Talisman Energy, Inc., Mosaic Company, Carrizo Oil & Gas, Petrohawk Energy Corp., United Therepeutics Corp., Black Diamond, Inc., Orient Express Hotels Ltd - A, Bioenvision Inc., Liveperson, Inc., DVI, Inc., Harris Stratex Networks, ICJ Medical, Inc., CV Therapeutics, and Middleby Corporation. Marcus Debaise is now subject to 17 customer disputes since 2011, many of which relate to the over-concentration of investor portfolios in equities.
HK: 9.00 (-0.31), TLM: 7.99 (unch), AMRN: 2.72 (-0.12), WFC: 47.12 (+0.16), MOS: 25.80 (-0.69), CRZO: 33.74 (-1.03)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 1.40 (unch), BIIB: 300.71 (+3.30), NWBO: 0.51 (-0.06), MBVX: 5.46 (+0.11), CVM: 0.39 (+0.01), CLDX: 3.66 (+0.08), MACK: 4.67 (+0.05), INO: 9.36 (+0.14), NLNK: 10.49 (+0.24), JUNO: 28.28 (-0.14), GALE: 0.32 (-0.03), IMMU: 2.91 (+0.06), ADXS: 10.54 (+0.14), ADRO: 13.70 (+0.10), IMGN: 2.84 (+0.08), AMGN: 169.96 (+0.66), SPPI: 5.05 (-0.44), LLY: 78.24 (-0.24), BMY: 55.33 (-0.27), GSK: 43.10 (+0.59), SRNE: 6.83 (+0.04), ONTY: 1.21 (+0.02), IMUC: 0.12 (unch), PGNX: 6.12 (+0.05), ARGS: 4.92 (+0.06), BLCM: 19.08 (+0.81), SGEN: 53.78 (+2.08), KITE: 54.63 (-0.47), MRK: 61.48 (-0.33)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 9.36 (+0.14), NWBO: 0.51 (-0.06), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), GALE: 0.32 (-0.03), GSK: 43.10 (+0.59), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Dendritic Cell and CAR-T Therapies Market, 2014 - 2024
PR Newswire - Tue Aug 18, 11:57AM CDT
INTRODUCTIONCancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeuticsincludingcell based therapies such as Dendritic Cell Therapy (DCT) and Chimeric Antigen Receptor T cell Therapy (CAR-T).
Global Cancer Immunotherapy Market Outlook 2020
M2 - Fri Jun 12, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3t28xc/global_cancer) has announced the addition of the "Global Cancer Immunotherapy Market Outlook 2020" report to their offering. Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects. Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years. Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts. Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data. New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future. Cancer Immunotherapies Included in Report: Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines "Global Cancer Immunotherapy Market Outlook 2020" Report Highlight: - Introduction & Classification of Cancer Immunotherapy - Global Cancer Immunotherapy Pipeline by Company, Indication & Phase - Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication - Global Cancer Immunotherapy Pipeline: 1834 Drugs - Marketed Cancer Immunotherapies: 113 Drugs - Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb - Cancer Vaccines Pipeline: 312 Vaccines - Marketed Cancer mAb: 36 mAb - Marketed Cancer Vaccines: 12 Vaccines Key Topics Covered: 1. Introduction to Cancer Immunotherapy 2. Classification of Cancer Immunotherapy 3. Cancer Immunotherapy by Vaccines 4. Cancer Immunotherapy by Monoclonal Antibodies 5. Cancer Immunotherapy by Adoptive Cell Transfer 6. Cancer Immunotherapy by Immune Checkpoint Inhibitors 7. Cancer Immunotherapy by Immunomodulators 8. Cancer Immunotherapy by Cytokines 9. Cancer Immunotherapy by Interleukins 10. Cancer Immunotherapy by Interferon 11. Cancer Immunotherapy by GM-CSF 12. Cancer Immunotherapy Market Overview 13. Global Cancer Immunotherapy Market Dynamics 14. Global Cancer Immunotherapy Market Future Prospects 15. Cancer Cell Therapies Clinical Pipeline by Company, Indication & Phase 16. Marketed Cancer Cell Therapies Drugs Clinical Insight 17. Cancer Cytokines Clinical Pipeline by Company, Indication & Phase 18. Marketed Cancer Cytokines Drugs Clinical Insight 19. Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase 20. Marketed Cancer Immunomodulators Clinical Insight 21. Cancer Vaccine Clinical Pipeline By Company, Indication & Phase 22. Marketed Cancer Vaccines Clinical Insight 23. Cancer Monoclonal Antibodies Clinical Pipeline by Company, Indication & Phase 24. Marketed Cancer Monoclonal Antibodies Drugs Clinical Insight 25. Competitive Landscape - Abbvie - Advaxis - Altor BioScience - Amgen - Biogen Idec - Biogenomics - Celldex Therapeutics - Dendreon Corporation - Eli Lilly - Expression Genetics - Galena Biopharma - Genmab - Gilead Sciences - GlaxoSmithKline - IRX Therapeutics - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Pfizer - Philogen - Regulon - Roche - Seattle Genetics - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/3t...bal_cancer
INO: 9.36 (+0.14), BIIB: 300.71 (+3.30), NWBO: 0.51 (-0.06), GILD: 77.76 (-0.30), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), AMGN: 169.96 (+0.66), GALE: 0.32 (-0.03), LLY: 78.24 (-0.24), GSK: 43.10 (+0.59), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 117.71 (+0.10), INO: 9.36 (+0.14), NWBO: 0.51 (-0.06), MRK: 61.48 (-0.33), CLDX: 3.66 (+0.08), NLNK: 10.49 (+0.24), GALE: 0.32 (-0.03), IMUC: 0.12 (unch), NVS: 79.21 (+0.09)
Should Investors Toss in the Towel on Amarin Corp Plc?
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Thu Mar 26, 11:02AM CDT
Investing in biotech is a risky business, and investing in emerging clinical stage companies doubly so. Many investors have jumped on the enticing bandwagon of the next blockbuster drug, only to have their hopes dashed before the promise is...
PFE: 33.96 (-0.08), AMRN: 2.72 (-0.12)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
BusinessWire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 27.46 (-0.07), VRX.TO: 36.21 (-0.08)
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)
CNW Group - Thu Feb 05, 9:30AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that yesterday it entered into an amended and restated "stalking horse" asset purchase agreement to acquire the world-wide rights to Dendreon's PROVENGE(®) (sipuleucel-T) product and certain other assets of Dendreon Corporation ("Dendreon"
. In response to competing bids, Valeant has raised its offer to $400 million in cash for the assets, which realized combined revenues of approximately $300 million in 2014. VRX: 27.46 (-0.07), VRX.TO: 36.21 (-0.08)
